Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases

COPENHAGEN, Denmark – 12th August 2026 – SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a kidney transplant recipient with progressive, multidrug-resistant Escherichia coli malakoplakia, a rare disease characterized by intracellular bacterial persistence.

The case report was conducted by leading infectious disease investigators at the University of California San Diego under a single-patient emergency investigational new drug (eIND) application, demonstrating the translational potential of SNIPR001 in a real-world compassionate-use setting.

SNIPR001 is SNIPR’s lead engineered CRISPR-enhanced medicine designed to selectively target E. coli. In the published case report, the patient received intravenous, topical, and intralesional administration of SNIPR001 in addition to standard-of-care therapy, including antibiotics and adjunctive treatments.

Treatment was associated with rapid healing of abdominal lesions and sustained radiographic regression of disease burden. The intra-abdominal malakoplakia mass decreased from 745 cm³ at baseline to 82 cm³ at one year, representing an 89% reduction. Follow-up urine and tissue cultures were negative following treatment, and no phage-related adverse events were reported during SNIPR001 administration.

“This case report marks an important clinical milestone for SNIPR001 and highlights the potential of our engineered CRISPR medicine platform to address difficult-to-treat, drug-resistant E. coli infections,” said Dr. Christian Grøndahl, CEO and co-founder of SNIPR. “We are grateful to the investigators at UC San Diego and to the patient and care team involved in this compassionate-use case, which provides valuable clinical insight into the potential role of SNIPR001 beyond prevention of bloodstream infections.”

SNIPR001 is currently being developed for the prevention of E. coli bloodstream infections in patients with hematological malignancies and is also being explored for the treatment of active E. coli infections. The publication adds to the growing clinical evidence base supporting the further development of engineered CRISPR medicines targeting drug-resistant E. coli infections.

Full PR available here